Electronic Injector for use with most standard and prefilled syringes Copyright September 2015
THE PROBLEM: No one likes injections or needles 7-22 % of the public is needle phobic For these patients, the prospect of injecting causes: a sick feeling and physical autonomic reactions, resulting in missed injections, resulting in poor treatment of underlying medical problems, resulting in lowered quality of life and medical complications. Self-injection requires skill, fortitude, and involves an amount of risk* *(improper positioning can cause bruising, tissue damage, incorrect dosage, and bent needles
THE SOLUTION: InnoJect Electronic Injector our technology makes it easy to perform self-injection simplifies and improves the injection process experience VISUAL: Hides the needle and syringe inside the injector applicator PHYSICAL: Provides tonal biofeedback for appropriate steadiness of orientation on skin surface Contains patent pending pain suppression technology AUDIO: Spoken instructions guide the user thru each step of injection (most languages are available) USABILITY: Gentle needle insertion, dispensing of medication, and needle retraction via electronic motion control Reminder timer for next injection (ringtone)
THESE: Standard Syringes and Prefilled-Syringes Go In here Patent Pending
Current Products on the Market & Weakness Not Competitors Insulin Pens (mechanical, manual needle insertion) Autoinjectors (spring fired, preloaded, single use, expensive) Autoinjectors (spring fired, loads limited range of syringes) Jet Injectors (not painless, limited to drugs approved for jet) Innoject is a New Market: Home administered drugs which have one of the following: no injection aid requires a larger needle than other injection devices can accommodate available injection aid is painful and scary to use These administered drugs totaled 13.7 million prescriptions in U.S. in 2007 (see next slide).
INNOJECT: MARKET ANALYSIS & TRENDS IN US TOTAL ACCESSIBLE MARKET: 17.5 million projected customers 56 million self-injectable prescriptions in the U.S. annual 35 million self-injectable prescriptions applicable to InnoJect usage* 17.5 million potential customers per annum** INITIAL TARGET MARKET: 68,000 projected customers per annum 13.7 million prescriptions are prime candidates for this market space*** 6.8 million projected customers available for capture** 1% capture rate = 68,000 InnoJects sold per annum U.S. 2007 NAMCS Data (National Ambulatory Medical Care Survey) and Insurance Survey for Drugs for Home Use by Blue Cross and Blue Shields 2007. *A percentage of the prescriptions for each drug applicable to our device, according to its specifics, is weighted and used to give a potential market. **Assumes that half the prescriptions are refills. ***Initial projected market share is based upon the number of pharmaceutical drugs most likely prescribed along with the InnoJect device, is weighted and number calculated.
Future Target Markets Medical facilities where NextGEN InnoJect model is utilized with multiple patients (1 device to multiple patients) International (underdeveloped countries) pharmaceutical drugs administered in treatment centers Immunizations stations Prefilled syringes NOT currently compatible with initial InnoJect model* * 2.5 billion prefilled syringes used worldwide in 2011.
Market Entry Scenario Contracts with the industry principle(s) for marketing function may be: distributors syringe manufacturers drug manufacturers who wants to distinguish themselves by solving the self-injection problem for their product. Market Entrance Scenario 1. Self-Injectable drugs are prescribed by a physician. 2. The physician sees our client, the patient. 3. InnoJect (Class II medical device) requires prescription. 4. The InnoJect turns a standard syringe or prefilled syringe into an autoinjector with finesse, effectively making the prospect of self injection an easy and much less scary task. 5. Doctor solves patient s self-injection problem by prescribing the InnoJect to the client along with prescribed self-injectable drug. 6. Client s costs covered by insurance company (part of marketing plan).
Model Production Timeline 1st Model -(Year 1): BASIC unit (home use*) (Entry point into market. Basis of Medicare Version.) 2nd Model - (Year 2): BASIC unit Plus* (New feature added: pain suppression technology ) 3rd Model - (Year 4): Multiple patient unit with twist-off needle shield. (Disposable sterile needle shields allow for repeat use on multiple patients. Provides repeat sales of disposable needle shields.) *Basic unit - home use/plus pain suppression models: patient purchases 1 unit that is reusable for multiple injections... not multiple patients.
Facts about the Fear of Needles Approximately 20 percent of the general population has some degree of fear associated with needles and injections. As much as 10 percent of people suffer from a phobia called trypanophobia, which is a fear of needles and injections. Traumatic experiences in childhood form the foundation of these fears like seeing an older sibling cry when getting their shots. Of those who have a fear of needles, at least 20 percent avoid medical treatment as a result. The fear of needles is both a learned and an inherited condition. A fairly small number inherit a fear of needles, but most people acquire needle phobia around age four to six. reference: Healthline.com
info@medifluidics Copyright September 2015